Tags

Type your tag names separated by a space and hit enter

Epidemiology of pertussis and Haemophilus influenzae type b disease in Canada with exclusive use of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b pediatric combination vaccine and an adolescent-adult tetanus-diphtheria-acellular pertussis vaccine: implications for disease prevention in the United States.
Pediatr Infect Dis J. 2009 Jun; 28(6):521-8.PI

Abstract

BACKGROUND

During the decade 1998-2007, a combination DTaP(5)-IPV/Hib vaccine was used exclusively in Canada to immunize infants and young children against diphtheria, tetanus, pertussis, polio, and invasive Haemophilus influenzae type b (Hib) disease.

METHODS

Medline was used to search for publications during 1996-2008 related to the epidemiology and vaccine prevention of pertussis and invasive Hib disease in Canada. Related abstracts and presentations were reviewed, when available, and epidemiologic data since 1985 were obtained from the Public Health Agency of Canada public Web site.

RESULTS

Reports of pertussis have declined substantially in preschool and school-aged children during the past decade, and cyclical peaks in disease incidence have been blunted or eliminated. In provinces and territories where Tdap(5) vaccine has been administered to 14- to 16-year-olds, marked reductions of pertussis have been documented in adolescents as well as younger age groups, possibly due to herd immunity. Incidence rates of invasive Hib disease among Canadian children <5 years declined markedly after introduction of Hib conjugate vaccines, and the disease has remained under control with exclusive use of DTaP(5)-IPV/Hib vaccine. Most cases of invasive Hib disease occur among unimmunized or only partially vaccinated children. The reduction of Hib case reports has been documented throughout Canada, including among Aboriginal children who are at high risk for this disease.

CONCLUSIONS

The Canadian experience with DTaP(5)-IPV/Hib and Tdap(5) vaccines is relevant to the United States because immunization schedules, vaccination coverage rates, and epidemiologic patterns of pertussis and Hib diseases are similar in the 2 countries, and because both vaccines are licensed for use in the United States.

Authors+Show Affiliations

Sanofi Pasteur Inc. Swiftwater, PA, USA. david.greenberg@sanofipasteur.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19436236

Citation

Greenberg, David P., et al. "Epidemiology of Pertussis and Haemophilus Influenzae Type B Disease in Canada With Exclusive Use of a Diphtheria-tetanus-acellular Pertussis-inactivated poliovirus-Haemophilus Influenzae Type B Pediatric Combination Vaccine and an Adolescent-adult Tetanus-diphtheria-acellular Pertussis Vaccine: Implications for Disease Prevention in the United States." The Pediatric Infectious Disease Journal, vol. 28, no. 6, 2009, pp. 521-8.
Greenberg DP, Doemland M, Bettinger JA, et al. Epidemiology of pertussis and Haemophilus influenzae type b disease in Canada with exclusive use of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b pediatric combination vaccine and an adolescent-adult tetanus-diphtheria-acellular pertussis vaccine: implications for disease prevention in the United States. Pediatr Infect Dis J. 2009;28(6):521-8.
Greenberg, D. P., Doemland, M., Bettinger, J. A., Scheifele, D. W., Halperin, S. A., Waters, V., & Kandola, K. (2009). Epidemiology of pertussis and Haemophilus influenzae type b disease in Canada with exclusive use of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b pediatric combination vaccine and an adolescent-adult tetanus-diphtheria-acellular pertussis vaccine: implications for disease prevention in the United States. The Pediatric Infectious Disease Journal, 28(6), 521-8. https://doi.org/10.1097/INF.0b013e318199d2fc
Greenberg DP, et al. Epidemiology of Pertussis and Haemophilus Influenzae Type B Disease in Canada With Exclusive Use of a Diphtheria-tetanus-acellular Pertussis-inactivated poliovirus-Haemophilus Influenzae Type B Pediatric Combination Vaccine and an Adolescent-adult Tetanus-diphtheria-acellular Pertussis Vaccine: Implications for Disease Prevention in the United States. Pediatr Infect Dis J. 2009;28(6):521-8. PubMed PMID: 19436236.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Epidemiology of pertussis and Haemophilus influenzae type b disease in Canada with exclusive use of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b pediatric combination vaccine and an adolescent-adult tetanus-diphtheria-acellular pertussis vaccine: implications for disease prevention in the United States. AU - Greenberg,David P, AU - Doemland,Martha, AU - Bettinger,Julie A, AU - Scheifele,David W, AU - Halperin,Scott A, AU - ,, AU - Waters,Valerie, AU - Kandola,Kami, PY - 2009/5/14/entrez PY - 2009/5/14/pubmed PY - 2009/9/1/medline SP - 521 EP - 8 JF - The Pediatric infectious disease journal JO - Pediatr Infect Dis J VL - 28 IS - 6 N2 - BACKGROUND: During the decade 1998-2007, a combination DTaP(5)-IPV/Hib vaccine was used exclusively in Canada to immunize infants and young children against diphtheria, tetanus, pertussis, polio, and invasive Haemophilus influenzae type b (Hib) disease. METHODS: Medline was used to search for publications during 1996-2008 related to the epidemiology and vaccine prevention of pertussis and invasive Hib disease in Canada. Related abstracts and presentations were reviewed, when available, and epidemiologic data since 1985 were obtained from the Public Health Agency of Canada public Web site. RESULTS: Reports of pertussis have declined substantially in preschool and school-aged children during the past decade, and cyclical peaks in disease incidence have been blunted or eliminated. In provinces and territories where Tdap(5) vaccine has been administered to 14- to 16-year-olds, marked reductions of pertussis have been documented in adolescents as well as younger age groups, possibly due to herd immunity. Incidence rates of invasive Hib disease among Canadian children <5 years declined markedly after introduction of Hib conjugate vaccines, and the disease has remained under control with exclusive use of DTaP(5)-IPV/Hib vaccine. Most cases of invasive Hib disease occur among unimmunized or only partially vaccinated children. The reduction of Hib case reports has been documented throughout Canada, including among Aboriginal children who are at high risk for this disease. CONCLUSIONS: The Canadian experience with DTaP(5)-IPV/Hib and Tdap(5) vaccines is relevant to the United States because immunization schedules, vaccination coverage rates, and epidemiologic patterns of pertussis and Hib diseases are similar in the 2 countries, and because both vaccines are licensed for use in the United States. SN - 0891-3668 UR - https://www.unboundmedicine.com/medline/citation/19436236/Epidemiology_of_pertussis_and_Haemophilus_influenzae_type_b_disease_in_Canada_with_exclusive_use_of_a_diphtheria_tetanus_acellular_pertussis_inactivated_poliovirus_Haemophilus_influenzae_type_b_pediatric_combination_vaccine_and_an_adolescent_adult_tetanus_diphtheria_acellular_pertussis_vaccine:_implications_for_disease_prevention_in_the_United_States_ L2 - https://doi.org/10.1097/INF.0b013e318199d2fc DB - PRIME DP - Unbound Medicine ER -